Novasep to Expand its HPAPI Capabilities at its France Site
The expansion in Le Mans, France will support growth in clinical and commercial manufacturing.
Novasep announced on May 12, 2021 that it plans to further expand its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities at its Le Mans, France site.
The expansion is Novasep’s next step in furthering its HPAPI and antibody drug conjugates (ADCs) expertise while continuing to offer its customers contract development and manufacturing capabilities for the production of targeted molecules to treat cancer, the company said in a press release.
“We are pleased to continue our development in strategic markets such as HPAPIs and ADCs, and to participate in the fight against cancer for the benefit of patients,” said Michel Spagnol, chairman and CEO of Novasep, in the press release. “Specifically, this expansion allows us to create more than 30 full-time jobs in Le Mans.”
Source: Novasep
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
